The reports discuss interim findings from an ongoing phase III extension study, which evaluates the safety of long-term vedolizumab treatment on patients with ulcerative colitis and Crohn’s disease. The data for these interim reports was collected between May 22, 2009 and June 27, 2013.
Here’s what you need to know:
1. The reports include outcomes of clinical response, remission and health-related quality of life factors, which were assessed for up to 152 weeks of treatment.
2. Patients with moderately to severely active ulcerative colitis reported clinical and health-related quality of life improvements with long-term vedolizumab treatment.
3. Patients with moderately to severely active Crohn’s disease reported clinical benefits with long-term vedolizumab treatment, regardless of prior tumor necrosis factor antagonist exposure.
More articles on gastroenterology and endoscopy:
What is the future of colorectal cancer screening? Still colonoscopy, says Dr. David A. Johnson
Predictive overbooking maximizes endoscopy clinic scheduling: 5 study insights
GI societies advocate for increased coverage of CRC screening, treatment: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.